Ipamorelin 5mg Research Peptide UK: Science and Lab Applications Guide
⚠️ Research Use Only. Ipamorelin 5mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product If you work in growth hormone research or study the ghrelin signalling pathway, the ipamorelin 5mg research peptide is likely already on your radar. Among the growth hormone-releasing peptides (GHRPs) available for laboratory research in the UK, ipamorelin occupies a scientifically distinctive position. It is the most receptor-selective GHRP studied in the published literature, offering isolated GH pathway stimulation in research models, with reported to have minimal effects on cortisol or prolactin in research models, two variables that complicate data interpretation when using less selective compounds. This guide covers everything UK-based researchers and laboratory professionals need to understand about the ipamorelin 5mg research peptide, its molecular identity and receptor pharmacology, how it differs from other GHRPs and from GHRH analogues like CJC-1295, its primary laboratory applications, and how to source it to the correct research-grade standard from a UK-based ipamorelin 5mg supplier. All content relates strictly to laboratory research, and any clinical or research data referenced is based on preclinical studies. Ascend Peptides UK supplies ipamorelin 5mg lab research peptide alongside our complete range of high-purity growth hormone research peptides for scientific investigation only, not for human consumption, veterinary, or clinical use. What is the Ipamorelin 5mg Research Peptide? Molecular Identity and Classification Ipamorelin is a synthetic pentapeptide, five amino acids in length, classified as a Growth Hormone Releasing Peptide (GHRP). It is a member of the growth hormone secretagogue (GHS) family of compounds: synthetic molecules that stimulate GH secretion by acting on the ghrelin receptor (GHS-R1a), an entirely different receptor system from the GHRH receptor (GHRHR) targeted by peptides like CJC-1295, without DAC and tesamorelin. The defining characteristic of the ipamorelin 5mg research peptide and the feature that most distinguishes it from other GHRPs in the literature is its exceptional receptor selectivity. In published research models, ipamorelin demonstrates highly selective GH stimulation with minimal effects on cortisol, prolactin, and ghrelin-mediated appetite signalling pathways. This selectivity profile makes it the preferred GHRP for research designs that require isolated GH pathway investigation without the confounding effects that less selective GHRPs introduce. Ipamorelin 5mg — Molecular Identity Quick Reference Identifier Value INN / Common name Ipamorelin Type Synthetic pentapeptide (5 amino acids) — GHRP Peptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 Molecular formula C38H49N9O5 Molecular weight 711.85 g/mol Primary receptor GHS-R1a (growth hormone secretagogue receptor 1a) Selectivity profile Highly selective in research models, with limited cortisol/prolactin effects reported Research category Growth Hormone Research Peptide (GHRP) Supplied form Lyophilised powder — white to off-white Format 5mg per vial (also available: 10mg) Third-party testing Janoshik — HPLC + LC-MS verified Understanding the Ghrelin System — The Scientific Foundation To understand why the ipamorelin 5mg research peptide is scientifically significant, it is necessary to first understand the receptor system it targets: the growth hormone secretagogue receptor 1a, or GHS-R1a, commonly known as the ghrelin receptor. Ghrelin is a naturally occurring peptide hormone produced primarily in the stomach, with the hypothalamus and pituitary gland also expressing ghrelin and its receptor. It plays a complex role in biological systems, influencing GH secretion, appetite regulation, energy homeostasis, and metabolic signalling. When ghrelin binds to GHS-R1a, one important effect in research models is stimulation of GH secretion from anterior pituitary somatotroph cells, a pathway entirely separate from, but complementary to, the GHRH-GHRHR pathway. This is a critical distinction for experimental design: the ghrelin pathway and the GHRH pathway represent two independent mechanisms by which GH secretion can be stimulated. Ipamorelin 5mg research peptide specifically targets the ghrelin pathway via GHS-R1a, while GHRH analogues like CJC-1295 without DAC target the GHRH pathway. In research models where both pathways are activated simultaneously, GH secretion is synergistically amplified, the mechanistic basis for why these two peptides are frequently studied together in combined-pathway research protocols. Mechanism of Action: How Ipamorelin 5mg Works in Laboratory Research The ipamorelin 5mg research peptide is studied as a selective agonist at GHS-R1a — the ghrelin receptor expressed on pituitary somatotroph cells, hypothalamic neurons, and other tissue types in relevant research models. When ipamorelin lab research peptide binds to GHS-R1a, it initiates the following signalling cascade in laboratory experimental systems: GHS-R1a activation → Gq protein stimulation → phospholipase C (PLC) activation → IP3 and DAG second messenger production IP3-mediated calcium release from intracellular stores → elevated intracellular Ca²⁺ → somatotroph cell activation DAG-mediated protein kinase C (PKC) activation → downstream GH gene expression and secretion Result: pulsatile GH secretion from anterior pituitary somatotroph cells The selectivity of the ipamorelin 5mg laboratory grade compound for GHS-R1a over other hormone pathways is a defining research advantage. In contrast to GHRP-6 and GHRP-2, two other GHRPs that activate GHS-R1a, ipamorelin demonstrates minimal activation of adrenocorticotropic hormone (ACTH) and cortisol release pathways, and is reported to have limited activation of ACTH, cortisol, and prolactin pathways in published research models. This selectivity means that experimental results reflect GH pathway activity specifically, rather than a combined hormonal response that complicates data interpretation. Ipamorelin 5mg vs Other GHRPs: Why Selectivity Matters in Research Researchers evaluating the ipamorelin 5mg research peptide alongside other GHRPs need to understand why selectivity is the central criterion for choosing between these compounds in laboratory settings. Property Ipamorelin 5mg GHRP-6 GHRP-2 Amino acids 5 (pentapeptide) 6 (hexapeptide) 6 (hexapeptide) Molecular weight 711.85 g/mol 873.04 g/mol 817.94 g/mol Receptor GHS-R1a (selective) GHS-R1a GHS-R1a GH stimulation ✓✓ Strong ✓✓ Strong ✓✓ Strong Cortisol effect ✓ Minimal in research models ✓✓ Notable increase ✓✓ Notable increase Prolactin effect ✓ Minimal in research models ✓✓ Notable increase ✓ Moderate increase Appetite pathway ✗ Minimal ghrelin effect ✓✓ Strong appetite stimulation ✓ Some effect Research selectivity ✓✓ Highest selectivity ✓ Moderate ✓ Moderate Best for Isolated GH pathway research Broad GH + appetite studies GH + cortisol
AOD-9604 10mg Research Peptide UK: Complete Advanced Laboratory Guide
⚠️ Research Use Only. AOD-9604 10mg is supplied strictly for in-vitro laboratory research purposes only. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All content below reflects peer-reviewed preclinical and published scientific literature only. This content is not medical advice. If your laboratory research programme has moved beyond preliminary investigation into AOD-9604 and requires a compound volume that supports full dose-response protocols, multi-arm experimental designs, and extended batch consistency, the AOD-9604 10mg research peptide is the appropriate format for your next phase of work. The AOD-9604 10mg research peptide is the advanced-format version of the most studied selective lipolysis compound in the UK metabolic research peptide category. Its defining scientific characteristic, selective stimulation of lipolysis through the beta-3 adrenergic receptor pathway without IGF-1 elevation or growth hormone receptor binding, is identical between both formats. What changes at 10mg is research capacity: the ability to run full concentration gradients, parallel experimental arms, and extended single-batch studies without the batch-change variability that limits multi-vial 5mg programmes. This guide is written specifically for UK-based researchers who are already familiar with AOD-9604 at the 5mg level and are evaluating the 10mg format for an established programme. For a complete introduction to AOD-9604 science, mechanism, and first-time research considerations, see our dedicated AOD-9604 5mg research peptide guide. All content relates strictly to laboratory research. The AOD-9604 10mg research peptide is supplied by Ascend Peptides UK for in-vitro research use only, not for human consumption, veterinary, or clinical application. What is the AOD-9604 10mg Research Peptide? AOD-9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH) — specifically, amino acids 176 through 191. The “AOD” designation stands for Anti-Obesity Drug, reflecting the original research objective when the compound was developed by scientists at Metabolic Pharmaceuticals in the 1990s. The compound includes a tyrosine (Tyr) residue added to the N-terminus of the native HGH fragment 176-191, a structural modification that distinguishes AOD-9604 from unmodified HGH Fragment 176-191 and contributes to its stability profile in laboratory conditions. The AOD-9604 10mg research peptide retains the defining pharmacological property of the parent fragment: selective stimulation of lipolysis, the breakdown of stored triglycerides in adipocyte cell models through a pathway independent of the growth hormone receptor (GHR) and independent of IGF-1 production. This IGF-1 independence is the single most important experimental advantage of the AOD 9604 10mg research compound for researchers designing metabolic studies: the absence of IGF-1 elevation means that downstream anabolic, mitogenic, or glucose-modulating confounds associated with full-length hGH are not present in AOD-9604 experimental models. AOD-9604 10mg Research Peptide — Molecular Identity Identifier Value Scientific name AOD-9604 (Anti-Obesity Drug 9604) Alternative names HGH Fragment 176-191 / Tyr-hGH Fragment 177-191 / GH Fragment Type Synthetic hexadecapeptide (16 amino acids) N-terminal modification Tyrosine (Tyr) residue added at the N-terminus Molecular formula C78H123N23O23S2 Molecular weight ~1,817.0 Da Origin C-terminal fragment (AA 176-191) of human growth hormone (hGH) Primary mechanism Selective lipolysis via the beta-3 adrenergic receptor pathway IGF-1 independence Does NOT stimulate IGF-1 production — key research advantage GHR binding Does NOT bind growth hormone receptor (GHR) Research category Metabolic Research Peptide Format (10mg) Lyophilised powder — white to off-white Testing standard Janoshik — HPLC + LC-MS verified, ≥98% purity Why Choose AOD-9604 10mg for Research? The Case for the Advanced Format The decision between AOD-9604 5mg and AOD-9604 10mg is not about which compound is superior; the molecular structure, mechanism of action, and purity standard are identical. The decision is about which format is appropriate for the scale and design of your research programme. The aod 9604 10mg research format becomes the correct choice when your experimental design requires one or more of the following: a full dose-response concentration gradient across multiple wells or treatment groups; parallel experimental arms comparing AOD-9604 with other metabolic research compounds; longitudinal studies requiring consistent compound conditions across multiple time points from a single batch; or high-throughput assay designs where vial-to-vial batch variation would introduce unacceptable experimental noise. Research Consideration AOD-9604 5mg AOD-9604 10mg Best suited for Pilot studies, method validation, preliminary investigations Established programmes, multi-arm studies, full dose-response Research stage First-time AOD-9604 research, assay development Confirmed research design, ongoing programme Dose-response range Limited concentration gradient Full dose-response curve capability Number of aliquots Fewer single-use aliquots per vial Greater aliquot volume — fewer batch changes Batch consistency Single-batch for focused pilot series Extended single-batch use — critical for reproducibility Multi-arm protocols Single-compound arms only Supports parallel compound arms simultaneously Cost efficiency Higher per mg — appropriate for pilot stage Better value for active research programmes Institutional suitability CRO pilots, academic method development Institutions, established CROs, multi-researcher labs Purity standard ≥98% HPLC-verified (Janoshik) ≥98% HPLC-verified (Janoshik — identical standard) For researchers beginning their first investigation with this compound and validating assay conditions before committing to a full programme, the AOD-9604 5mg research peptide guide covers the pilot-stage format in detail, including first-time reconstitution protocols and preliminary dose selection considerations. Mechanism of Action: How AOD-9604 10mg Works in Laboratory Research Models Understanding the mechanism of the AOD-9604 10mg research peptide at a molecular level is essential for designing valid experimental protocols and correctly attributing observed outcomes to the compound’s specific activity. Three mechanistic properties define how AOD-9604 behaves in research models. 1. Beta-3 Adrenergic Receptor (β3-AR) Pathway Activation The primary documented mechanism of AOD-9604 in laboratory research models is activation of the beta-3 adrenergic receptor (β3-AR), a G-protein-coupled receptor expressed predominantly in adipose tissue. β3-AR activation triggers a cAMP-mediated signalling cascade that activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), the two primary enzymes responsible for triglyceride hydrolysis in adipocytes. The result is liberation of free fatty acids and glycerol, the defining outcome measured in lipolysis assays using the AOD 9604 10mg research compound. 2. IGF-1 Independence — The Key Research Advantage Unlike full-length hGH, the AOD-9604 10mg research peptide does not bind the growth hormone receptor (GHR) and does not stimulate IGF-1 production through the liver. This independence from the GH-IGF-1 axis is the most
Sermorelin 2mg Research Peptide UK: Complete GHRH Science Guide
⚠️ Research Use Only. Sermorelin 2mg is supplied strictly for in-vitro laboratory research purposes only. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All content below reflects peer-reviewed preclinical and published scientific literature only. This content is not medical advice. Among the GHRH research peptides available to UK laboratories, the sermorelin 2mg research peptide occupies a scientifically distinct position not because it is the most potent or the longest-acting, but because it is the most physiologically representative. As a synthetic analogue of the first 29 amino acids of native Growth Hormone Releasing Hormone, sermorelin produces pulsatile GH stimulation with the shortest in vitro half-life of any GHRH research analogue, approximately 12 minutes, making it the most accurate molecular tool available for studying the natural kinetics of GHRH receptor activation without the extended DPP-IV protection of modified analogues like CJC-1295 or tesamorelin. The sermorelin 2mg research peptide is the entry-format version of this GHRH analogue appropriate for pilot investigations, pharmacokinetic time-course studies, method development, and first-time GHRH receptor research before scaling to the 5mg format for established programmes. This guide covers its molecular identity, the scientific basis of its unique research value, how it compares to other GHRH analogues, and how to source it from a UK-based sermorelin peptide supplier with same-day dispatch. All content relates strictly to laboratory research. Ascend Peptides UK supplies sermorelin 2mg laboratory grade as part of our complete range of growth hormone research peptides for UK laboratories for in-vitro research use only, not for human consumption, veterinary, or clinical application. What is the Sermorelin 2mg Research Peptide? Molecular Identity Sermorelin, known scientifically as GRF 1-29 NH2, or GHRH(1-29)NH2, is a synthetic peptide corresponding to the first 29 amino acids of the naturally occurring 44-amino acid Growth Hormone Releasing Hormone. Unlike tesamorelin, which replicates the full 44-amino acid GHRH sequence with N-terminal stabilisation, or CJC-1295 without DAC, which introduces four amino acid substitutions for enhanced DPP-IV resistance, sermorelin makes no structural modifications to the first 29 amino acids of native GHRH. It is, in that sense, the most structurally conservative GHRH research analogue, the one most closely resembling the natural ligand. This structural conservatism is both sermorelin’s defining research advantage and its primary pharmacokinetic limitation. Because it carries no DPP-IV protection beyond that provided by the native GHRH sequence itself, the sermorelin 2mg research peptide is degraded relatively rapidly by dipeptidyl aminopeptidase IV in research conditions, producing an in vitro half-life of approximately 12 minutes. This is the shortest half-life of all three major GHRH research analogues, and, for appropriately designed studies, this kinetic property is precisely what makes sermorelin the correct compound to choose. Sermorelin 2mg Research Peptide — Molecular Identity Quick Reference Identifier Value Scientific name Sermorelin (INN) Alternative names GRF 1-29 NH2 / GHRH(1-29)NH2 / Sermorelin Acetate Type Synthetic truncated GHRH analogue — 29 amino acids Molecular formula C149H246N44O42S Molecular weight 3,357.93 Da Receptor target GHRHR (Growth Hormone Releasing Hormone Receptor) — Gs-coupled GPCR Amino acid coverage First 29 AA of native GHRH (44 AA full length) DPP-IV resistance Moderate — less resistant than tesamorelin or CJC-1295 In vitro half-life ~12 minutes — shortest of all GHRH research analogues GH pulse pattern Pulsatile — mirrors natural GH secretion closely Research category Growth Hormone Research Peptide (GHRH Analogue) Format (2mg) Lyophilised powder — white to off-white Testing standard Janoshik — HPLC + LC-MS verified, ≥98% purity How the Sermorelin 2mg Research Peptide Works — GHRHR Signalling The sermorelin 2mg research peptide acts as a selective agonist at the Growth Hormone Releasing Hormone Receptor (GHRHR), a Gs-coupled G-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Upon binding to GHRHR, sermorelin initiates the following signalling cascade in laboratory research models: GHRHR activation → Gs protein stimulation → adenylyl cyclase activation → intracellular cAMP elevation Elevated cAMP → protein kinase A (PKA) activation → phosphorylation of downstream transcription factors PKA activation → increased GH mRNA transcription → pulsatile growth hormone secretion from somatotroph cells GH secretion → hepatic IGF-1 production → downstream growth factor signalling cascade The key mechanistic distinction for experimental design is the relationship between sermorelin’s short half-life and the GH pulse pattern it produces in research models. Because sermorelin is cleared rapidly from the experimental system, approximately 12 minutes, it produces discrete, well-defined GH secretion pulses that closely mirror the natural pulsatile pattern of endogenous GHRH activity. This physiological accuracy makes the ghrh research peptide sermorelin the preferred compound for time-course studies examining GH pulse amplitude, frequency, and decay kinetics, areas where longer-acting analogues like CJC-1295 without DAC produce sustained stimulation that masks these natural dynamics. Why Choose the 2mg Format? Sermorelin 2mg vs 5mg for Research The choice between sermorelin 2mg and sermorelin 5mg is a research-stage decision, not a quality decision. The molecular structure, GHRHR binding affinity, mechanism of action, and purity standard are identical across both formats. What differs is the research capacity each format provides. Research Consideration Sermorelin 2mg Sermorelin 5mg Best suited for Pilot studies, short-term assay validation, and pharmacokinetic profiling Established programmes, extended longitudinal studies, multi-arm designs Research stage First-time sermorelin research, method development Confirmed design, ongoing programme with validated methods Half-life study design Ideal for repeated pulsatile stimulation assays — shorter windows Extended multi-dose pulsatile protocols across longer timeframes Aliquots available Fewer aliquots — sufficient for focused experimental series Greater aliquot volume — fewer batch changes in extended studies Batch consistency Single-batch for pilot series Extended single-batch — critical for longitudinal reproducibility Cost efficiency Higher per mg — appropriate for pilot stage Better value for active research programmes Comparative studies Single-arm GHRH comparison studies Multi-arm GHRH analogue comparisons alongside CJC-1295, tesamorelin Purity standard ≥98% HPLC-verified (Janoshik) ≥98% HPLC-verified (Janoshik — identical) The sermorelin 2mg laboratory grade format is particularly well-suited to the compound’s primary research application: pharmacokinetic and pulsatile dynamics studies. Because these protocols typically involve multiple small-volume time-point samples rather than large-volume treatment groups, the 2mg format provides sufficient compound volume for a complete pulsatile time-course experimental series without requiring the full
